PMV Pharmaceuticals, Inc. releases Q3 results, emphasizing ongoing research and development efforts in the competitive pharmaceutical sector.
| Name | PMV Pharmaceuticals, Inc. |
|---|---|
| CIK | 0001699382 |
| Tickers | PMVP |
| Exchanges | Nasdaq |
| Entity type | operating |
| Category | Non-accelerated filer<br>Smaller reporting company |
| SIC | 2834 Pharmaceutical Preparations |
| EIN | 463218129 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | DE DE |
| Phone | (609) 642-6670 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
PMV Pharmaceuticals, Inc. releases Q3 results, emphasizing ongoing research and development efforts in the competitive pharmaceutical sector.
PMV Pharmaceuticals reports its Q3 2026 financial results, showcasing its performance and future outlook in the pharmaceutical preparations industry.
PMV Pharmaceuticals enhances its board with Dr. Matthew Eckler's appointment, aiming for accelerated drug approval in 2027.
394 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | 8-K | 8-K | 8.01,9.01 | 0001193125-26-470247 | 001-39539 | 261579232 | 34 | 175696 | 1 | 1 |
| 2026-11-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001214659-26-014414 | 005-91714 | 261561111 | 34 | 18471 | |||
| 2026-11-10 | 10-Q | 10-Q | 0001193125-26-454471 | 001-39539 | 261538040 | 34 | 9635248 | 1 | 1 | |
| 2026-11-10 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-454467 | 001-39539 | 261538024 | 34 | 395467 | 1 | 1 |
| 2026-10-05 | 4 | xslF345X06/form4-10052026_081058.xml | 0002156044-26-000004 | 5570 | ||||||
| 2026-10-05 | 3 | xslF345X06/form3-10052026_081055.xml | 0002156044-26-000002 | 8187 | ||||||
| 2026-10-05 | 8-K | 8-K | 5.02,7.01,9.01 | 0001193125-26-413254 | 001-39539 | 261438926 | 34 | 161807 | 1 | 1 |
| 2026-09-15 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0001699737-26-000021 | 005-91714 | 261382021 | 34 | 20440 | |||
| 2026-09-02 | 8-K | 8-K | 1.01,8.01,9.01 | 0001193125-26-378838 | 001-39539 | 261352112 | 34 | 870990 | 1 | 1 |
| 2026-09-02 | 424B5 | 424B5 | 0001193125-26-378780 | 333-283349 | 261352032 | 33 | 635498 | |||
| 2026-08-31 | 424B3 | 424B3 | 0001193125-26-377000 | 333-283349 | 261347424 | 33 | 55608 | |||
| 2026-08-31 | 424B5 | 424B5 | 0001193125-26-376860 | 333-283349 | 261346876 | 33 | 656877 | |||
| 2026-08-31 | 8-K | 8-K | 8.01,9.01 | 0001193125-26-376723 | 001-39539 | 261346455 | 34 | 161850 | 1 | 1 |
| 2026-08-14 | 10-Q | 10-Q | 0001193125-26-350448 | 001-39539 | 261276230 | 34 | 8177119 | 1 | 1 | |
| 2026-08-14 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-350445 | 001-39539 | 261276216 | 34 | 366049 | 1 | 1 |
| 2026-07-28 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001214659-26-009110 | 005-91714 | 261212677 | 34 | 8661 | |||
| 2026-07-10 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001172661-26-002568 | 005-91714 | 261167602 | 34 | 7103 | |||
| 2026-06-05 | 4 | xslF345X06/form4-06052026_080643.xml | 0001644348-26-000003 | 5571 | ||||||
| 2026-06-05 | 4 | xslF345X06/form4-06052026_080603.xml | 0001124164-26-000002 | 5599 | ||||||
| 2026-06-05 | 4 | xslF345X06/form4-06052026_080616.xml | 0001329959-26-000002 | 10010 | ||||||
| 2026-06-05 | 4 | xslF345X06/form4-06052026_080614.xml | 0001797209-26-000002 | 5591 | ||||||
| 2026-06-05 | 4 | xslF345X06/form4-06052026_080642.xml | 0001579824-26-000003 | 5593 | ||||||
| 2026-06-05 | 8-K | 8-K | 5.07 | 0001193125-26-258466 | 001-39539 | 261066915 | 34 | 145417 | 1 | 1 |
| 2026-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001012975-26-000440 | 005-91714 | 26986934 | 34 | 16504 | |||
| 2026-05-12 | 10-Q | 10-Q | 0001193125-26-218227 | 001-39539 | 26965929 | 34 | 7348707 | 1 | 1 | |
| 2026-05-12 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-218225 | 001-39539 | 26965924 | 34 | 332252 | 1 | 1 |
| 2026-05-04 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001214659-26-005496 | 005-91714 | 26937757 | 34 | 8671 | |||
| 2026-04-22 | ARS | ARS | 0001140361-26-016040 | 001-39539 | 26881340 | 34 | 1813182 | |||
| 2026-04-22 | DEFA14A | DEFA14A | 0001140361-26-016039 | 001-39539 | 26881333 | 34 | 3269571 | |||
| 2026-04-22 | DEF 14A | DEF 14A | 0001140361-26-016038 | 001-39539 | 26881324 | 34 | 5383047 | 1 | 1 | |
| 2026-03-09 | 4 | xslF345X05/form4-03092026_080319.xml | 0002006668-26-000002 | 6315 | ||||||
| 2026-03-09 | 4 | xslF345X05/form4-03092026_080354.xml | 0001613482-26-000002 | 5427 | ||||||
| 2026-03-09 | 4 | xslF345X05/form4-03092026_080350.xml | 0001825192-26-000002 | 5439 | ||||||
| 2026-03-09 | 4 | xslF345X05/form4-03092026_080314.xml | 0001341642-26-000002 | 5407 | ||||||
| 2026-03-06 | S-8 | S-8 | 0001193125-26-095224 | 333-294078 | 26728723 | 33 | 190268 | 1 | 1 | |
| 2026-03-06 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-095094 | 001-39539 | 26728540 | 34 | 326915 | 1 | 1 |
| 2026-03-06 | 10-K | 10-K | 0001193125-26-095014 | 001-39539 | 26728498 | 34 | 13142643 | 1 | 1 | |
| 2026-03-04 | SCHEDULE 13D/A | xslSCHEDULE_13D_X01/primary_doc.xml | 0000947871-26-000231 | 005-91714 | 26723899 | 34 | 25125 | |||
| 2026-02-17 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001172661-26-001163 | 005-91714 | 26642472 | 34 | 6932 | |||
| 2026-02-09 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001373604-26-000014 | 005-91714 | 26610922 | 34 | 6482 | |||
| 2025-11-12 | 10-Q | 10-Q | 0001193125-25-276003 | 001-39539 | 251469049 | 34 | 8350957 | 1 | 1 | |
| 2025-11-12 | 8-K | 8-K | 2.02,9.01 | 0001193125-25-276000 | 001-39539 | 251469035 | 34 | 380997 | 1 | 1 |
| 2025-11-12 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001214659-25-016264 | 005-91714 | 251469030 | 34 | 8648 | |||
| 2025-10-29 | 4 | xslF345X05/form4-10292025_081048.xml | 0001341642-25-000004 | 10206 | ||||||
| 2025-10-27 | 4 | xslF345X05/ownership.xml | 0000947871-25-000927 | 8064 | ||||||
| 2025-10-27 | SCHEDULE 13D/A | xslSCHEDULE_13D_X01/primary_doc.xml | 0000947871-25-000926 | 005-91714 | 251420613 | 34 | 24598 | |||
| 2025-10-23 | 144 | xsl144X01/primary_doc.xml | 0000947871-25-000922 | 001-39539 | 251413964 | 33 | 5524 | |||
| 2025-09-23 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001214659-25-014073 | 005-91714 | 251335005 | 34 | 26261 | |||
| 2025-09-12 | 4 | xslF345X05/ownership.xml | 0000947871-25-000854 | 8059 | ||||||
| 2025-09-10 | 144 | xsl144X01/primary_doc.xml | 0000947871-25-000847 | 001-39539 | 251306873 | 33 | 4842 | |||
| 2025-09-10 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-25-199857 | 001-39539 | 251305186 | 34 | 5546978 | 1 | 1 |
| 2025-08-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001104659-25-078560 | 005-91714 | 251218528 | 34 | 12887 | |||
| 2025-08-13 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001214659-25-011954 | 005-91714 | 251210504 | 34 | 8572 | |||
| 2025-08-07 | 10-Q | 10-Q | 0000950170-25-104588 | 001-39539 | 251191700 | 34 | 8156328 | 1 | 1 | |
| 2025-08-07 | 8-K | 8-K | 2.02,9.01 | 0000950170-25-104587 | 001-39539 | 251191698 | 34 | 326803 | 1 | 1 |
| 2025-07-03 | 4 | xslF345X05/form4-07032025_110750.xml | 0001415889-25-019386 | 5043 | ||||||
| 2025-07-03 | 4 | xslF345X05/form4-07032025_110708.xml | 0001415889-25-019384 | 4860 | ||||||
| 2025-07-03 | 4 | xslF345X05/form4-07032025_110716.xml | 0001415889-25-019382 | 4873 | ||||||
| 2025-07-03 | 4 | xslF345X05/form4-07032025_110757.xml | 0001415889-25-019380 | 7939 | ||||||
| 2025-06-09 | 4 | xslF345X05/form4-06092025_080633.xml | 0001415889-25-016276 | 5404 | ||||||
| 2025-06-09 | 4 | xslF345X05/form4-06092025_080646.xml | 0001415889-25-016269 | 5462 | ||||||
| 2025-06-09 | 4 | xslF345X05/form4-06092025_080655.xml | 0001415889-25-016266 | 5409 | ||||||
| 2025-06-09 | 4 | xslF345X05/form4-06092025_080644.xml | 0001415889-25-016262 | 9873 | ||||||
| 2025-06-09 | 4 | xslF345X05/form4-06092025_080616.xml | 0001415889-25-016259 | 5454 | ||||||
| 2025-06-09 | 4 | xslF345X05/form4-06092025_080615.xml | 0001415889-25-016254 | 5456 | ||||||
| 2025-06-09 | 8-K | 8-K | 5.07 | 0001193125-25-137497 | 001-39539 | 251032946 | 34 | 145431 | 1 | 1 |
| 2025-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001104659-25-049430 | 005-91714 | 25952925 | 34 | 13433 | |||
| 2025-05-09 | 10-Q | 10-Q | 0000950170-25-067513 | 001-39539 | 25928434 | 34 | 7744889 | 1 | 1 | |
| 2025-05-09 | 8-K | 8-K | 2.02,9.01 | 0000950170-25-067511 | 001-39539 | 25928430 | 34 | 329147 | 1 | 1 |
| 2025-04-25 | ARS | ARS | 0001140361-25-015613 | 001-39539 | 25870197 | 34 | 1804473 | |||
| 2025-04-25 | DEFA14A | DEFA14A | 0001140361-25-015612 | 001-39539 | 25870191 | 34 | 819612 | |||
| 2025-04-25 | DEF 14A | DEF 14A | 0001140361-25-015610 | 001-39539 | 25870182 | 34 | 5388996 | 1 | 1 | |
| 2025-04-23 | 3 | xslF345X02/form3-04232025_100400.xml | 0001415889-25-011229 | 15021 | ||||||
| 2025-04-08 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001214659-25-005584 | 005-91714 | 25821591 | 34 | 8461 | |||
| 2025-03-05 | 4 | xslF345X05/form4-03052025_110309.xml | 0001415889-25-007075 | 5440 | ||||||
| 2025-03-05 | 4 | xslF345X05/form4-03052025_110323.xml | 0001415889-25-007073 | 6445 | ||||||
| 2025-03-05 | 4 | xslF345X05/form4-03052025_110346.xml | 0001415889-25-007071 | 9359 | ||||||
| 2025-03-03 | 10-K | 10-K | 0000950170-25-030414 | 001-39539 | 25694122 | 34 | 14347350 | 1 | 1 | |
| 2025-03-03 | 8-K | 8-K | 2.02,9.01 | 0000950170-25-030407 | 001-39539 | 25693821 | 34 | 374436 | 1 | 1 |
| 2025-02-21 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001104659-25-016122 | 005-91714 | 25651605 | 34 | 20033 | |||
| 2025-02-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001373604-25-000029 | 005-91714 | 25624419 | 34 | 6599 | |||
| 2025-02-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001373604-25-000028 | 005-91714 | 25624334 | 34 | 6500 | |||
| 2025-02-10 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001214659-25-002314 | 005-91714 | 25604796 | 34 | 8473 | |||
| 2025-01-28 | S-8 | S-8 | 0001193125-25-014448 | 333-284560 | 25565283 | 33 | 88080 | |||
| 2025-01-22 | 4 | xslF345X05/form4-01222025_090129.xml | 0001415889-25-001853 | 13403 | ||||||
| 2024-12-12 | SC 13G | pmvp13g.htm | 0001373604-24-000110 | 005-91714 | 241543941 | 34 | 56216 | |||
| 2024-11-27 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2024-11-27 16:30:00 | 9999999995-24-003606 | 333-283349 | 241512993 | 33 | 1779 | ||
| 2024-11-27 | 424B3 | 424B3 | 0001193125-24-267229 | 333-283349 | 241511958 | 33 | 379120 | |||
| 2024-11-25 | CORRESP | filename1.htm | 0001193125-24-265243 | 7645 | ||||||
| 2024-11-25 | UPLOAD | filename1.pdf | 0000000000-24-013056 | 333-283349 | 40095 | |||||
| 2024-11-20 | S-3 | S-3 | 0001193125-24-262148 | 333-283349 | 241478317 | 33 | 885874 | |||
| 2024-11-14 | SC 13G/A | arrowmark-pmvp093024a1.htm | 0001172661-24-004898 | 005-91714 | 241459350 | 34 | 53978 | |||
| 2024-11-07 | 10-Q | 10-Q | 0000950170-24-122817 | 001-39539 | 241433267 | 34 | 7331079 | 1 | 1 | |
| 2024-11-07 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-122816 | 001-39539 | 241433262 | 34 | 365451 | 1 | 1 |
| 2024-10-03 | 4 | xslF345X05/form4-10032024_081022.xml | 0001415889-24-024627 | 15553 | ||||||
| 2024-10-03 | 4 | xslF345X05/form4-10032024_081040.xml | 0001415889-24-024624 | 15544 | ||||||
| 2024-10-03 | 4 | xslF345X05/form4-10032024_081002.xml | 0001415889-24-024622 | 15532 | ||||||
| 2024-09-12 | 4 | xslF345X05/form4-09122024_100948.xml | 0001415889-24-023313 | 4799 | ||||||
| 2024-09-12 | 4 | xslF345X05/form4-09122024_090908.xml | 0001415889-24-023309 | 4793 | ||||||
| 2024-08-14 | SC TO-I/A | SC TO-I/A | 0001193125-24-200605 | 005-91714 | 241207342 | 34 | 18398 | |||
| 2024-08-08 | 10-Q | 10-Q | 0000950170-24-093343 | 001-39539 | 241186131 | 34 | 6872547 | 1 | 1 | |
| 2024-08-08 | 8-K | 8-K | 1.02,2.02,9.01 | 0000950170-24-093345 | 001-39539 | 241186126 | 34 | 456949 | 1 | 1 |
| 2024-07-16 | SC TO-I | SC TO-I | 0001193125-24-179366 | 005-91714 | 241118646 | 34 | 10864389 | |||
| 2024-07-08 | SC 13G/A | us69353y1038_070824.txt | 0001086364-24-008191 | 005-91714 | 241105173 | 34 | 12764 | |||
| 2024-06-10 | 4 | xslF345X05/form4-06102024_080637.xml | 0001415889-24-016238 | 10250 | ||||||
| 2024-06-10 | 4 | xslF345X05/form4-06102024_080620.xml | 0001415889-24-016236 | 10185 | ||||||
| 2024-06-10 | 4 | xslF345X05/form4-06102024_080647.xml | 0001415889-24-016214 | 10277 | ||||||
| 2024-06-10 | 4 | xslF345X05/form4-06102024_080606.xml | 0001415889-24-016208 | 14786 | ||||||
| 2024-06-10 | 4 | xslF345X05/form4-06102024_080652.xml | 0001415889-24-016202 | 10304 | ||||||
| 2024-06-10 | 4 | xslF345X05/form4-06102024_080633.xml | 0001415889-24-016199 | 10349 | ||||||
| 2024-06-07 | 8-K | 8-K | 5.07 | 0001193125-24-156745 | 001-39539 | 241027470 | 34 | 150560 | 1 | 1 |
| 2024-05-09 | 10-Q | 10-Q | 0000950170-24-056295 | 001-39539 | 24928673 | 34 | 6362863 | 1 | 1 | |
| 2024-05-09 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-056294 | 001-39539 | 24928662 | 34 | 301722 | 1 | 1 |
| 2024-04-24 | ARS | ARS | 0001140361-24-021598 | 001-39539 | 24866773 | 34 | 1803681 | |||
| 2024-04-24 | DEFA14A | DEFA14A | 0001140361-24-021597 | 001-39539 | 24866767 | 34 | 1934310 | |||
| 2024-04-24 | DEF 14A | DEF 14A | 0001140361-24-021596 | 001-39539 | 24866759 | 34 | 2833775 | |||
| 2024-04-09 | SC 13G/A | FILING PMV PHARMACEUTICALS, INC. | 0000019617-24-000303 | 005-91714 | 34 | 89739 | ||||
| 2024-02-29 | 10-K | 10-K | 0000950170-24-023062 | 001-39539 | 24703571 | 34 | 25571024 | 1 | 1 | |
| 2024-02-29 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-023058 | 001-39539 | 24703529 | 34 | 331169 | 1 | 1 |
| 2024-02-14 | SC 13G/A | SC 13G/A | 0001104659-24-023955 | 005-91714 | 24640025 | 34 | 137699 | |||
| 2024-02-14 | SC 13G/A | ff3027171_13ga3-pmv.htm | 0000895345-24-000060 | 005-91714 | 24637541 | 34 | 171192 | |||
| 2024-02-14 | SC 13G | arrowmark-pmvp123123.htm | 0001172661-24-001360 | 005-91714 | 24636985 | 34 | 53957 | |||
| 2024-02-14 | SC 13G/A | PMV PHARMACEUTICALS, INC. | 0000902664-24-001604 | 005-91714 | 24633016 | 34 | 57894 | |||
| 2024-02-14 | SC 13G/A | PMV PHARMACEUTICALS, INC. | 0000902664-24-001575 | 005-91714 | 24632392 | 34 | 61794 | |||
| 2024-02-13 | SC 13G/A | SCHEDULE 13G/A | 0001104659-24-021730 | 005-91714 | 24629297 | 34 | 12999 | |||
| 2024-01-29 | SC 13G/A | us69353y1038_012924.txt | 0001086364-24-005056 | 005-91714 | 24573074 | 34 | 13327 | |||
| 2024-01-24 | S-8 | S-8 | 0001193125-24-013722 | 333-276667 | 24554452 | 33 | 82213 | |||
| 2024-01-23 | SC 13G/A | FILING PMV PHARMACEUTICALS, INC. | 0000019617-24-000129 | 005-91714 | 34 | 89951 | ||||
| 2024-01-23 | SC 13G/A | PMV_Pharma_Inc.txt | 0000093751-24-000075 | 005-91714 | 24550593 | 34 | 8355 | |||
| 2024-01-22 | 4 | FORM 4 SUBMISSION | 0001209191-24-001999 | 9920 | ||||||
| 2024-01-22 | 4 | FORM 4 SUBMISSION | 0001209191-24-001995 | 7176 | ||||||
| 2024-01-22 | 4 | FORM 4 SUBMISSION | 0001209191-24-001993 | 12545 | ||||||
| 2024-01-18 | 8-K | 8-K | 2.05,7.01,9.01 | 0001193125-24-010177 | 001-39539 | 24541775 | 34 | 163862 | 1 | 1 |
| 2024-01-11 | 3 | FORM 3 SUBMISSION | 0001209191-24-001449 | 10792 | ||||||
| 2024-01-05 | 8-K | 8-K | 5.02,7.01,9.01 | 0001193125-24-003348 | 001-39539 | 24516171 | 34 | 174826 | 1 | 1 |
| 2023-11-24 | 4 | xslF345X05/ownership.xml | 0000947871-23-001104 | 11069 | ||||||
| 2023-11-22 | 144 | xsl144X01/primary_doc.xml | 0000947871-23-001098 | 001-39539 | 231433460 | 33 | 4662 | |||
| 2023-11-13 | 4 | FORM 4 SUBMISSION | 0001209191-23-054997 | 12238 | ||||||
| 2023-11-09 | 10-Q | 10-Q | 0000950170-23-061551 | 001-39539 | 231390140 | 34 | 7758467 | 1 | 1 | |
| 2023-11-09 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-061552 | 001-39539 | 231390136 | 34 | 426937 | 1 | 1 |
| 2023-10-12 | 8-K | 8-K | 8.01,9.01 | 0001193125-23-255083 | 001-39539 | 231323301 | 34 | 3102726 | 1 | 1 |
| 2023-10-11 | 8-K | 8-K | 7.01,9.01 | 0001193125-23-254135 | 001-39539 | 231320714 | 34 | 164009 | 1 | 1 |
| 2023-09-18 | 4 | FORM 4 SUBMISSION | 0001209191-23-049759 | 4765 | ||||||
| 2023-09-18 | 4 | FORM 4 SUBMISSION | 0001209191-23-049751 | 4759 | ||||||
| 2023-08-23 | SC 13D/A | AMENDMENT NO. 2 | 0000947871-23-000902 | 005-91714 | 231198176 | 34 | 110742 | |||
| 2023-08-09 | 10-Q | 10-Q | 0000950170-23-040153 | 001-39539 | 231153433 | 34 | 8393515 | 1 | 1 | |
| 2023-08-09 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-040151 | 001-39539 | 231153423 | 34 | 473996 | 1 | 1 |
| 2023-08-08 | 4 | FORM 4 SUBMISSION | 0001209191-23-045010 | 9753 | ||||||
| 2023-07-07 | SC 13G/A | us69353y1038_070723.txt | 0001306550-23-009586 | 005-91714 | 231077295 | 34 | 13377 | |||
| 2023-06-12 | 4 | FORM 4 SUBMISSION | 0001209191-23-036456 | 5269 | ||||||
| 2023-06-12 | 4 | FORM 4 SUBMISSION | 0001209191-23-036449 | 5327 | ||||||
| 2023-06-12 | 4 | FORM 4 SUBMISSION | 0001209191-23-036427 | 5282 | ||||||
| 2023-06-12 | 4 | FORM 4 SUBMISSION | 0001209191-23-036383 | 10010 | ||||||
| 2023-06-12 | 4 | FORM 4 SUBMISSION | 0001209191-23-036373 | 5319 | ||||||
| 2023-06-12 | 4 | FORM 4 SUBMISSION | 0001209191-23-036368 | 5321 | ||||||
| 2023-06-09 | 8-K | 8-K | 5.07 | 0001193125-23-164011 | 001-39539 | 231003903 | 34 | 149838 | 1 | 1 |
| 2023-05-19 | SC 13G | SC 13G | 0001104659-23-062680 | 005-91714 | 23940008 | 34 | 131537 | |||
| 2023-05-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-029612 | 5331 | ||||||
| 2023-05-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-029609 | 5323 | ||||||
| 2023-05-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-029594 | 5288 | ||||||
| 2023-05-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-029586 | 5279 | ||||||
| 2023-05-10 | SC 13G/A | PMV_PHARMACEUTICALS_INC.txt | 0000093751-23-000561 | 005-91714 | 23904601 | 34 | 8291 | |||
| 2023-05-10 | 10-Q | 10-Q | 0000950170-23-020100 | 001-39539 | 23904410 | 34 | 7838162 | 1 | 1 | |
| 2023-05-10 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-020097 | 001-39539 | 23904402 | 34 | 391843 | 1 | 1 |
| 2023-04-28 | EFFECT | xslEFFECTX01/primary_doc.xml | POS AM,0001193125-23-056275,2023-04-28 | 9999999995-23-001090 | 333-260012 | 23869665 | 33 | 1680 | ||
| 2023-04-28 | ARS | ARS | 0001140361-23-021225 | 001-39539 | 23860293 | 34 | 1937941 | |||
| 2023-04-28 | DEFA14A | DEFA14A | 0001140361-23-021223 | 001-39539 | 23860282 | 34 | 2574606 | |||
| 2023-04-28 | 8-K | 8-K | 5.03,9.01 | 0001193125-23-124381 | 001-39539 | 23860271 | 34 | 360673 | 1 | 1 |
| 2023-04-28 | DEF 14A | DEF14A | 0001140361-23-021220 | 001-39539 | 23860268 | 34 | 2754088 | |||
| 2023-03-01 | POS AM | POS AM | 0001193125-23-056275 | 333-260012 | 23693327 | 33 | 1271892 | |||
| 2023-03-01 | 10-K | 10-K | 0000950170-23-005345 | 001-39539 | 23689852 | 34 | 14383149 | 1 | 1 | |
| 2023-03-01 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-005343 | 001-39539 | 23689843 | 34 | 393622 | 1 | 1 |
| 2023-03-01 | POSASR | POSASR | 0001193125-23-055105 | 333-260012 | 23689666 | 33 | 1329499 | |||
| 2023-02-14 | SC 13G/A | ff0001742120_13ga-pmv.htm | 0000895345-23-000138 | 005-91714 | 23626170 | 34 | 166268 | |||
| 2023-02-14 | SC 13G/A | PMV PHARMACEUTICALS, INC. | 0000902664-23-001721 | 005-91714 | 23623851 | 34 | 64066 | |||
| 2023-02-14 | SC 13G/A | PMV PHARMACEUTICALS, INC. | 0000902664-23-001676 | 005-91714 | 23623488 | 34 | 58687 | |||
| 2023-02-14 | SC 13G/A | SC 13G/A | 0001104659-23-020811 | 005-91714 | 23622833 | 34 | 137772 | |||
| 2023-02-10 | SC 13G/A | SC 13G/A | 0001193125-23-032082 | 005-91714 | 23610050 | 34 | 107496 | |||
| 2023-02-10 | SC 13G/A | PMV_Pharmaceuticals_Inc.txt | 0000093751-23-000444 | 005-91714 | 23609499 | 34 | 10252 | |||
| 2023-02-09 | SC 13G/A | SCHEDULE 13G/A | 0001104659-23-016743 | 005-91714 | 23604026 | 34 | 12920 | |||
| 2023-01-31 | SC 13G/A | us69353y1038_013123.txt | 0001306550-23-005159 | 005-91714 | 23571819 | 34 | 13249 | |||
| 2023-01-30 | 4 | FORM 4 SUBMISSION | 0001209191-23-005476 | 4638 | ||||||
| 2023-01-25 | SC 13G/A | FILING PMV PHARMACEUTICALS, INC. | 0000019617-23-000152 | 005-91714 | 34 | 89736 | ||||
| 2023-01-25 | S-8 | S-8 | 0001193125-23-014435 | 333-269394 | 23549438 | 33 | 102123 | |||
| 2023-01-24 | SC 13G/A | COWEN FINANCIAL PRODUCTS LLC | 0001085146-23-000338 | 005-91714 | 23547800 | 34 | 27166 | |||
| 2022-11-08 | 4 | FORM 4 SUBMISSION | 0001209191-22-056102 | 9933 | ||||||
| 2022-11-08 | 3 | FORM 3 SUBMISSION | 0001209191-22-056097 | 5090 | ||||||
| 2022-11-08 | 10-Q | 10-Q | 0000950170-22-022920 | 001-39539 | 221367321 | 34 | 8615086 | 1 | 1 | |
| 2022-11-08 | 8-K | 8-K | 2.02,9.01 | 0000950170-22-022919 | 001-39539 | 221367313 | 34 | 487178 | 1 | 1 |
| 2022-11-04 | 8-K | 8-K | 5.02,7.01,9.01 | 0001193125-22-277423 | 001-39539 | 221360220 | 34 | 162113 | 1 | 1 |
| 2022-09-13 | 4 | FORM 4 SUBMISSION | 0001209191-22-049694 | 4771 | ||||||
| 2022-09-13 | 4 | FORM 4 SUBMISSION | 0001209191-22-049692 | 4758 | ||||||
| 2022-08-09 | 10-Q | 10-Q | 0000950170-22-015767 | 001-39539 | 221146474 | 34 | 7563832 | 1 | 1 | |
| 2022-08-09 | 8-K | 8-K | 2.02,9.01 | 0000950170-22-015768 | 001-39539 | 221146469 | 34 | 485731 | 1 | 1 |
| 2022-07-11 | SC 13G | PMV_PHARMACEUTICALS_INC.txt | 0000093751-22-000570 | 005-91714 | 221076519 | 34 | 10202 | |||
| 2022-07-07 | SC 13G/A | FILING PMV PHARMACEUTICALS, INC. | 0000019617-22-000407 | 005-91714 | 34 | 89788 | ||||
| 2022-06-17 | SC 13G | PMV PHARMACEUTICALS, INC. | 0001104659-22-072372 | 005-91714 | 221023690 | 34 | 133739 | |||
| 2022-06-08 | 8-K | 8-K | 7.01,9.01 | 0001193125-22-169686 | 001-39539 | 221002524 | 34 | 10763552 | 1 | 1 |
| 2022-06-06 | 4 | FORM 4 SUBMISSION | 0001209191-22-034634 | 5224 | ||||||
| 2022-06-06 | 4 | FORM 4 SUBMISSION | 0001209191-22-034622 | 5297 | ||||||
| 2022-06-06 | 4 | FORM 4 SUBMISSION | 0001209191-22-034620 | 5252 | ||||||
| 2022-06-06 | 4 | FORM 4 SUBMISSION | 0001209191-22-034618 | 5289 | ||||||
| 2022-06-06 | 4 | FORM 4 SUBMISSION | 0001209191-22-034607 | 5289 | ||||||
| 2022-06-06 | 8-K | 8-K | 5.07 | 0001193125-22-168285 | 001-39539 | 22997964 | 34 | 161195 | 1 | 1 |
| 2022-05-31 | 4 | xslF345X03/ownership.xml | 0000947871-22-000675 | 11722 | ||||||
| 2022-05-26 | 8-K | 8-K | 7.01,9.01 | 0001564590-22-021434 | 001-39539 | 22971081 | 34 | 202495 | 1 | 1 |
| 2022-05-10 | 10-Q | 10-Q | 0001564590-22-019071 | 001-39539 | 22907348 | 34 | 6236542 | 1 | 1 | |
| 2022-05-10 | 8-K | 8-K | 2.02,9.01 | 0001564590-22-019070 | 001-39539 | 22907339 | 34 | 372882 | 1 | 1 |
| 2022-04-29 | 4 | FORM 4 SUBMISSION | 0001209191-22-026341 | 10038 | ||||||
| 2022-04-22 | DEFA14A | DEFA14A | 0001140361-22-015509 | 001-39539 | 22843422 | 34 | 3963869 | |||
| 2022-04-22 | DEF 14A | DEF 14A | 0001140361-22-015508 | 001-39539 | 22843418 | 34 | 2635475 | |||
| 2022-04-21 | 4 | FORM 4 SUBMISSION | 0001209191-22-025171 | 8579 | ||||||
| 2022-04-01 | SC 13D/A | AMENDMENT NO. 1 | 0000947871-22-000432 | 005-91714 | 22799290 | 34 | 140870 | |||
| 2022-03-31 | 4 | xslF345X03/ownership.xml | 0000947871-22-000429 | 17469 | ||||||
| 2022-03-09 | 4 | FORM 4 SUBMISSION | 0001209191-22-017591 | 11624 | ||||||
| 2022-03-01 | 10-K | 10-K | 0001564590-22-007860 | 001-39539 | 22693934 | 34 | 15496548 | 1 | 1 | |
| 2022-03-01 | 8-K | 8-K | 2.02,9.01 | 0001564590-22-007858 | 001-39539 | 22693927 | 34 | 398531 | 1 | 1 |
| 2022-02-28 | 4 | FORM 4 SUBMISSION | 0001209191-22-013576 | 5303 | ||||||
| 2022-02-28 | 4 | FORM 4 SUBMISSION | 0001209191-22-013569 | 5293 | ||||||
| 2022-02-28 | 4 | FORM 4 SUBMISSION | 0001209191-22-013557 | 5258 | ||||||
| 2022-02-28 | 4 | FORM 4 SUBMISSION | 0001209191-22-013544 | 5249 | ||||||
| 2022-02-14 | SC 13G/A | SC 13G/A | 0001140361-22-005366 | 005-91714 | 22634250 | 34 | 251228 | |||
| 2022-02-14 | SC 13G/A | SC 13G/A | 0001193125-22-041754 | 005-91714 | 22632202 | 34 | 85821 | |||
| 2022-02-14 | SC 13G/A | SC 13G/A | 0001104659-22-022624 | 005-91714 | 22631031 | 34 | 123781 | |||
| 2022-02-14 | SC 13G | PMV PHARMACEUTICALS, INC. | 0000902664-22-001593 | 005-91714 | 22625679 | 34 | 69523 | |||
| 2022-02-14 | SC 13G/A | SC 13G/A | 0001193125-22-039392 | 005-91714 | 22625163 | 34 | 163708 | |||
| 2022-02-14 | SC 13G/A | SC 13G/A | 0001193125-22-039277 | 005-91714 | 22625014 | 34 | 105447 | |||
| 2022-02-11 | SC 13G/A | PMV PHARMACEUTICALS, INC. | 0000902664-22-001525 | 005-91714 | 22617356 | 34 | 59175 | |||
| 2022-02-10 | SC 13G | SCHEDULE 13G | 0001104659-22-018348 | 005-91714 | 22610617 | 34 | 12886 | |||
| 2022-02-08 | 4 | FORM 4 SUBMISSION | 0001209191-22-007754 | 4623 | ||||||
| 2022-02-04 | SC 13G | us69353y1038_020422.txt | 0000834237-22-007153 | 005-91714 | 22593443 | 34 | 13303 | |||
| 2022-01-26 | SC 13G | FILING PMV PHARMACEUTICALS, INC. | 0000019617-22-000187 | 005-91714 | 34 | 89742 | ||||
| 2022-01-24 | S-8 | S-8 | 0001193125-22-016010 | 333-262308 | 22549316 | 33 | 68961 | |||
| 2022-01-19 | SC 13G | COWEN FINANCIAL PRODUCTS LLC | 0001085146-22-000226 | 005-91714 | 22538552 | 34 | 27128 | |||
| 2022-01-10 | 4 | FORM 4 SUBMISSION | 0001209191-22-002722 | 5231 | ||||||
| 2022-01-10 | 3 | FORM 3 SUBMISSION | 0001209191-22-002718 | 5045 | ||||||
| 2022-01-06 | 8-K | FORM 8-K | 5.02,7.01,9.01 | 0001193125-22-003158 | 001-39539 | 22513660 | 34 | 166314 | 1 | 1 |
| 2021-12-16 | 4 | FORM 4 SUBMISSION | 0001209191-21-070116 | 11622 | ||||||
| 2021-11-12 | 10-Q | 10-Q | 0001564590-21-056458 | 001-39539 | 211399556 | 34 | 7250984 | 1 | 1 | |
| 2021-11-12 | 8-K | 8-K | 2.02,9.01 | 0001564590-21-056451 | 001-39539 | 211399529 | 34 | 440142 | 1 | 1 |
| 2021-10-18 | SC 13G/A | SC 13G/A | 0001193125-21-300999 | 005-91714 | 211328281 | 34 | 165724 | |||
| 2021-10-08 | 4 | FORM 4 SUBMISSION | 0001209191-21-060100 | 5864 | ||||||
| 2021-10-05 | 8-K | FORM 8-K | 1.01,9.01 | 0001193125-21-292044 | 001-39539 | 211306668 | 34 | 411556 | 1 | 1 |
| 2021-10-04 | 4 | FORM 4 SUBMISSION | 0001209191-21-059163 | 9841 | ||||||
| 2021-10-04 | S-3ASR | S-3ASR | 0001193125-21-290972 | 333-260012 | 211302959 | 33 | 971777 | |||
| 2021-09-29 | 4 | FORM 4 SUBMISSION | 0001209191-21-058091 | 8114 | ||||||
| 2021-09-24 | 4 | FORM 4 SUBMISSION | 0001209191-21-057711 | 5342 | ||||||
| 2021-09-23 | 4 | FORM 4 SUBMISSION | 0001209191-21-057515 | 4674 | ||||||
| 2021-09-21 | 4 | FORM 4 SUBMISSION | 0001209191-21-057099 | 5864 | ||||||
| 2021-09-13 | 4 | FORM 4 SUBMISSION | 0001209191-21-055782 | 12614 | ||||||
| 2021-09-10 | 4 | FORM 4 SUBMISSION | 0001209191-21-055438 | 8662 | ||||||
| 2021-09-08 | 4 | FORM 4 SUBMISSION | 0001209191-21-055140 | 8667 | ||||||
| 2021-09-02 | 4 | FORM 4 SUBMISSION | 0001209191-21-054604 | 10364 | ||||||
| 2021-08-30 | 4 | FORM 4 SUBMISSION | 0001209191-21-053964 | 14863 | ||||||
| 2021-08-25 | 4 | FORM 4 SUBMISSION | 0001209191-21-053389 | 12613 | ||||||
| 2021-08-24 | 4 | FORM 4 SUBMISSION | 0001209191-21-053179 | 4674 | ||||||
| 2021-08-20 | 4 | FORM 4 SUBMISSION | 0001209191-21-052822 | 12613 | ||||||
| 2021-08-20 | 4 | FORM 4 SUBMISSION | 0001209191-21-052787 | 8593 | ||||||
| 2021-08-20 | 4 | FORM 4 SUBMISSION | 0001209191-21-052784 | 8564 | ||||||
| 2021-08-18 | 4 | FORM 4 SUBMISSION | 0001209191-21-052248 | 9148 | ||||||
| 2021-08-17 | 4 | FORM 4 SUBMISSION | 0001209191-21-051994 | 17113 | ||||||
| 2021-08-13 | 10-Q | 10-Q | 0001564590-21-044131 | 001-39539 | 211169595 | 34 | 6821025 | 1 | 1 | |
| 2021-08-13 | 8-K | 8-K | 2.02,9.01 | 0001564590-21-044128 | 001-39539 | 211169578 | 34 | 293634 | ||
| 2021-08-12 | 4 | FORM 4 SUBMISSION | 0001209191-21-051285 | 14863 | ||||||
| 2021-08-10 | 4 | FORM 4 SUBMISSION | 0001209191-21-050670 | 12663 | ||||||
| 2021-08-09 | 4 | FORM 4 SUBMISSION | 0001209191-21-050501 | 19359 | ||||||
| 2021-08-04 | 4 | FORM 4 SUBMISSION | 0001209191-21-049728 | 18839 | ||||||
| 2021-08-04 | 4 | FORM 4 SUBMISSION | 0001209191-21-049724 | 10782 | ||||||
| 2021-07-30 | 4 | FORM 4 SUBMISSION | 0001209191-21-048965 | 8113 | ||||||
| 2021-07-27 | 4 | FORM 4 SUBMISSION | 0001209191-21-048335 | 10362 | ||||||
| 2021-07-23 | 4 | FORM 4 SUBMISSION | 0001209191-21-047988 | 7591 | ||||||
| 2021-07-23 | 4 | FORM 4 SUBMISSION | 0001209191-21-047970 | 5189 | ||||||
| 2021-07-22 | 4 | FORM 4 SUBMISSION | 0001209191-21-047747 | 7503 | ||||||
| 2021-07-22 | 4 | FORM 4 SUBMISSION | 0001209191-21-047745 | 16072 | ||||||
| 2021-07-14 | 4 | FORM 4 SUBMISSION | 0000899243-21-028387 | 20508 | ||||||
| 2021-07-08 | 4 | FORM 4 SUBMISSION | 0001209191-21-046054 | 10301 | ||||||
| 2021-07-08 | 4 | FORM 4 SUBMISSION | 0001209191-21-045989 | 11021 | ||||||
| 2021-06-29 | 4 | FORM 4 SUBMISSION | 0001209191-21-043738 | 10327 | ||||||
| 2021-06-22 | 4 | FORM 4 SUBMISSION | 0001209191-21-042460 | 7027 | ||||||
| 2021-06-15 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-21-005709 | 32422 | ||||||
| 2021-06-11 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-21-005572 | 32368 | ||||||
| 2021-06-09 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-21-005496 | 45772 | ||||||
| 2021-06-09 | 4 | FORM 4 SUBMISSION | 0001209191-21-039245 | 5875 | ||||||
| 2021-06-09 | 4 | FORM 4 SUBMISSION | 0001209191-21-039241 | 5226 | ||||||
| 2021-06-09 | 4 | FORM 4 SUBMISSION | 0001209191-21-039239 | 5298 | ||||||
| 2021-06-09 | 4 | FORM 4 SUBMISSION | 0001209191-21-039237 | 5253 | ||||||
| 2021-06-09 | 4 | FORM 4 SUBMISSION | 0001209191-21-039235 | 5291 | ||||||
| 2021-06-08 | 4 | FORM 4 SUBMISSION | 0001209191-21-039038 | 5303 | ||||||
| 2021-06-08 | 4 | FORM 4 SUBMISSION | 0001209191-21-039035 | 13335 | ||||||
| 2021-06-08 | 4 | FORM 4 SUBMISSION | 0001209191-21-039032 | 5264 | ||||||
| 2021-06-08 | 4 | FORM 4 SUBMISSION | 0001209191-21-039028 | 5246 | ||||||
| 2021-06-07 | 4 | FORM 4 SUBMISSION | 0001209191-21-038798 | 10301 | ||||||
| 2021-06-07 | 8-K | 8-K | 5.07 | 0001193125-21-184010 | 001-39539 | 21998791 | 34 | 25153 | ||
| 2021-06-04 | 4 | FORM 4 SUBMISSION | 0001209191-21-038419 | 8595 | ||||||
| 2021-06-02 | 4 | FORM 4 SUBMISSION | 0001209191-21-037377 | 5863 | ||||||
| 2021-06-02 | 4 | FORM 4 SUBMISSION | 0001209191-21-037144 | 34825 | ||||||
| 2021-05-27 | 4 | FORM 4 SUBMISSION | 0001209191-21-036352 | 8112 | ||||||
| 2021-05-24 | 4 | FORM 4 SUBMISSION | 0001209191-21-035544 | 10363 | ||||||
| 2021-05-24 | 4 | FORM 4 SUBMISSION | 0001209191-21-035364 | 16373 | ||||||
| 2021-05-21 | 4 | FORM 4 SUBMISSION | 0001209191-21-035034 | 7026 | ||||||
| 2021-05-21 | S-8 | FORM S-8 | 0001193125-21-168601 | 333-256346 | 21946624 | 33 | 79451 | |||
| 2021-05-14 | 10-Q | 10-Q | 0001564590-21-027813 | 001-39539 | 21921993 | 34 | 5115815 | 1 | ||
| 2021-05-14 | 8-K | 8-K | 2.02,9.01 | 0001564590-21-027811 | 001-39539 | 21921981 | 34 | 264688 | ||
| 2021-05-12 | 4 | FORM 4 SUBMISSION | 0001209191-21-032222 | 5863 | ||||||
| 2021-05-12 | 4 | FORM 4 SUBMISSION | 0000899243-21-019183 | 20458 | ||||||
| 2021-05-10 | 4 | FORM 4 SUBMISSION | 0001209191-21-031300 | 11013 | ||||||
| 2021-05-07 | 4 | FORM 4 SUBMISSION | 0001209191-21-031052 | 5862 | ||||||
| 2021-05-07 | SC 13G/A | SC 13G/A | 0001193125-21-155060 | 005-91714 | 21903744 | 34 | 152578 | |||
| 2021-05-07 | 3 | INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-21-004263 | 20664 | ||||||
| 2021-05-04 | 4 | FORM 4 SUBMISSION | 0001209191-21-030096 | 12336 | ||||||
| 2021-04-23 | DEFA14A | DEFA14A | 0001140361-21-014038 | 001-39539 | 21846785 | 34 | 270918 | |||
| 2021-04-23 | DEF 14A | DEF 14A | 0001140361-21-014036 | 001-39539 | 21846779 | 34 | 1872017 | |||
| 2021-04-13 | 4 | FORM 4 SUBMISSION | 0001209191-21-026547 | 14336 | ||||||
| 2021-04-08 | 4 | FORM 4 SUBMISSION | 0001209191-21-026157 | 16590 | ||||||
| 2021-04-08 | 4 | FORM 4 SUBMISSION | 0001209191-21-026064 | 11013 | ||||||
| 2021-04-07 | 4 | FORM 4 SUBMISSION | 0001209191-21-025880 | 5227 | ||||||
| 2021-04-07 | 3 | FORM 3 SUBMISSION | 0001209191-21-025874 | 5836 | ||||||
| 2021-04-06 | 8-K | 8-K | 5.02,7.01,9.01 | 0001193125-21-107069 | 001-39539 | 21808210 | 34 | 32911 | ||
| 2021-04-05 | 4 | FORM 4 SUBMISSION | 0001209191-21-025463 | 10365 | ||||||
| 2021-03-31 | 4 | FORM 4 SUBMISSION | 0001209191-21-023909 | 22872 | ||||||
| 2021-03-26 | 4 | FORM 4 SUBMISSION | 0001209191-21-023299 | 21593 | ||||||
| 2021-03-25 | 4 | FORM 4 SUBMISSION | 0000899243-21-013532 | 20463 | ||||||
| 2021-03-03 | 10-K | 10-K | 0001564590-21-010578 | 001-39539 | 21709153 | 34 | 11440435 | 1 | ||
| 2021-03-03 | 8-K | 8-K | 2.02,9.01 | 0001564590-21-010576 | 001-39539 | 21709123 | 34 | 214960 | ||
| 2021-02-16 | SC 13G | SC 13G | 0001104659-21-023842 | 005-91714 | 21637714 | 34 | 97732 | |||
| 2021-02-16 | SC 13G/A | AMENDMENT NO. 1 | 0001387131-21-002334 | 005-91714 | 21631248 | 34 | 206383 | |||
| 2021-02-12 | SC 13G | SC 13G | 0001193125-21-041409 | 005-91714 | 21626985 | 34 | 142610 | |||
| 2021-02-12 | SC 13G | PMV PHARMACEUTICALS, INC. | 0000902664-21-001243 | 005-91714 | 21622926 | 34 | 61870 | |||
| 2021-02-12 | SC 13G | SC 13G | 0001193125-21-039677 | 005-91714 | 21622525 | 34 | 113990 | |||
| 2020-12-31 | 4 | FORM 4 SUBMISSION | 0001209191-20-065683 | 9134 | ||||||
| 2020-11-20 | 4 | FORM 4 SUBMISSION | 0001209191-20-059634 | 8922 | ||||||
| 2020-11-13 | 10-Q | 10-Q | 0001564590-20-053908 | 001-39539 | 201312356 | 34 | 6423378 | 1 | ||
| 2020-11-13 | 8-K | 8-K | 2.02,9.01 | 0001564590-20-053736 | 001-39539 | 201309252 | 34 | 290517 | ||
| 2020-11-12 | 4 | FORM 4 SUBMISSION | 0001209191-20-057925 | 5985 | ||||||
| 2020-10-05 | SC 13D | SCHEDULE 13D | 0000947871-20-000773 | 005-91714 | 201224547 | 34 | 144446 | |||
| 2020-10-05 | SC 13G | ACQUISITION OF BENEFICIAL OWNERSHIP | 0001387131-20-008767 | 005-91714 | 201224345 | 34 | 161244 | |||
| 2020-10-02 | 4/A | FORM 4/A SUBMISSION | 0001209191-20-053346 | 21879 | ||||||
| 2020-10-02 | 4/A | FORM 4/A SUBMISSION | 0001209191-20-053342 | 26960 | ||||||
| 2020-09-30 | SC 13G | SC 13G | 0001193125-20-259677 | 005-91714 | 201212601 | 34 | 102329 | |||
| 2020-09-29 | 4 | FORM 4 SUBMISSION | 0001209191-20-052353 | 18021 | ||||||
| 2020-09-29 | 4 | FORM 4 SUBMISSION | 0001209191-20-052351 | 7462 | ||||||
| 2020-09-29 | 4 | FORM 4 SUBMISSION | 0001209191-20-052350 | 31828 | ||||||
| 2020-09-29 | 4 | FORM 4 SUBMISSION | 0001209191-20-052349 | 3224 | ||||||
| 2020-09-29 | 4 | FORM 4 SUBMISSION | 0001209191-20-052347 | 2996 | ||||||
| 2020-09-29 | 4 | FORM 4 SUBMISSION | 0001209191-20-052346 | 3000 | ||||||
| 2020-09-29 | 4 | FORM 4 SUBMISSION | 0001209191-20-052341 | 27699 | ||||||
| 2020-09-29 | 4 | FORM 4 SUBMISSION | 0001209191-20-052339 | 35318 | ||||||
| 2020-09-29 | 4 | FORM 4 SUBMISSION | 0001209191-20-052337 | 30373 | ||||||
| 2020-09-29 | 4 | FORM 4 SUBMISSION | 0001209191-20-052336 | 11865 | ||||||
| 2020-09-29 | 4 | FORM 4 SUBMISSION | 0001209191-20-052335 | 26754 | ||||||
| 2020-09-29 | 4 | FORM 4 SUBMISSION | 0001209191-20-052334 | 21674 | ||||||
| 2020-09-29 | 3/A | FORM 3/A SUBMISSION | 0001209191-20-052333 | 12580 | ||||||
| 2020-09-29 | 4 | OWNERSHIP DOCUMENT | 0001104659-20-109853 | 14176 | ||||||
| 2020-09-29 | 8-K | 8-K | 5.03,7.01,9.01 | 0001193125-20-257820 | 001-39539 | 201209015 | 34 | 212968 | ||
| 2020-09-28 | S-8 | S-8 | 0001193125-20-256300 | 333-249094 | 201204378 | 33 | 92467 | |||
| 2020-09-25 | 424B4 | 424B4 | 0001193125-20-254551 | 333-248627 | 201200144 | 33 | 3703260 | |||
| 2020-09-24 | EFFECT | xslEFFECTX01/primary_doc.xml | S-1,,2020-09-24 16:00:00 | 9999999995-20-002572 | 333-248627 | 201196713 | 33 | 1662 | ||
| 2020-09-24 | 3 | OWNERSHIP DOCUMENT | 0001104659-20-108403 | 9084 | ||||||
| 2020-09-24 | 3 | FORM 3 SUBMISSION | 0001209191-20-052031 | 4706 | ||||||
| 2020-09-24 | 3 | FORM 3 SUBMISSION | 0001209191-20-052030 | 6604 | ||||||
| 2020-09-24 | 3 | FORM 3 SUBMISSION | 0001209191-20-052029 | 14152 | ||||||
| 2020-09-24 | 3 | FORM 3 SUBMISSION | 0001209191-20-052026 | 19741 | ||||||
| 2020-09-24 | 3 | FORM 3 SUBMISSION | 0001209191-20-052022 | 6200 | ||||||
| 2020-09-24 | 3 | FORM 3 SUBMISSION | 0001209191-20-052015 | 5938 | ||||||
| 2020-09-24 | 3 | FORM 3 SUBMISSION | 0001209191-20-052011 | 5946 | ||||||
| 2020-09-24 | 3 | FORM 3 SUBMISSION | 0001209191-20-052007 | 14362 | ||||||
| 2020-09-24 | 3 | FORM 3 SUBMISSION | 0001209191-20-052005 | 14958 | ||||||
| 2020-09-24 | 3 | FORM 3 SUBMISSION | 0001209191-20-052003 | 6547 | ||||||
| 2020-09-24 | 3 | FORM 3 SUBMISSION | 0001209191-20-052001 | 8590 | ||||||
| 2020-09-24 | 3 | FORM 3 SUBMISSION | 0001209191-20-051999 | 14311 | ||||||
| 2020-09-24 | 3 | FORM 3 SUBMISSION | 0001209191-20-051998 | 9727 | ||||||
| 2020-09-24 | 3 | FORM 3 SUBMISSION | 0001209191-20-051997 | 5961 | ||||||
| 2020-09-24 | 3 | FORM 3 SUBMISSION | 0001209191-20-051996 | 18574 | ||||||
| 2020-09-24 | 3 | FORM 3 SUBMISSION | 0001209191-20-051995 | 7856 | ||||||
| 2020-09-24 | 3 | FORM 3 SUBMISSION | 0001209191-20-051994 | 6640 | ||||||
| 2020-09-24 | 3 | FORM 3 SUBMISSION | 0001209191-20-051993 | 10029 | ||||||
| 2020-09-24 | 3 | FORM 3 SUBMISSION | 0001209191-20-051991 | 12025 | ||||||
| 2020-09-24 | CERT | 8A_Cert_PMVP.pdf | 0001354457-20-000522 | 001-39539 | 201193877 | 34 | 140356 | |||
| 2020-09-24 | S-1/A | S-1/A | 0001193125-20-252783 | 333-248627 | 201193483 | 33 | 3806936 | |||
| 2020-09-22 | CORRESP | filename1.htm | 0001193125-20-251102 | 9949 | ||||||
| 2020-09-22 | CORRESP | filename1.htm | 0001193125-20-251101 | 10782 | ||||||
| 2020-09-21 | 8-A12B | 8-A12B | 0001193125-20-250157 | 001-39539 | 201186382 | 34 | 14012 | |||
| 2020-09-21 | CORRESP | filename1.htm | 0001193125-20-249576 | 20453 | ||||||
| 2020-09-21 | S-1/A | S-1/A | 0001193125-20-249570 | 333-248627 | 201185145 | 33 | 4992826 | |||
| 2020-09-17 | UPLOAD | filename1.pdf | 0000000000-20-008764 | 44376 | ||||||
| 2020-09-11 | CORRESP | filename1.htm | 0001193125-20-243785 | 134965 | ||||||
| 2020-09-04 | CORRESP | filename1.htm | 0001193125-20-240145 | 25056 | ||||||
| 2020-09-04 | S-1 | S-1 | 0001193125-20-240132 | 333-248627 | 201162228 | 33 | 5764670 | |||
| 2020-08-18 | UPLOAD | filename1.pdf | 0000000000-20-007585 | 45918 | ||||||
| 2020-08-03 | DRS/A | filename1.htm | 0000950123-20-007493 | 377-03247 | 201067321 | 33 | 3786081 | |||
| 2020-07-31 | DRSLTR | filename1.htm | 0000950123-20-007494 | 59338 | ||||||
| 2020-07-23 | UPLOAD | filename1.pdf | 0000000000-20-006725 | 67032 | ||||||
| 2020-06-26 | DRS | filename1.htm | 0000950123-20-006405 | 377-03247 | 20993917 | 33 | 3398053 | |||
| 2017-03-02 | D | xslFormDX01/primary_doc.xml | 06b | 0001699382-17-000001 | 021-281658 | 17658233 | 33 | 8769 |
One latest value per concept from companyfacts (226 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| dei | EntityCommonStockSharesOutstanding | Entity Common Stock, Shares Outstanding | shares | 75.53M | 2026-11-10 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| dei | EntityPublicFloat | Entity Public Float | USD | 53.44M | 2025-06-30 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 | |
| ecd | NonPeoNeoAvgCompActuallyPaidAmt | NonPeoNeoAvgCompActuallyPaidAmt | USD | 662,535 | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-22 | 0001140361-26-016038 | ||
| ecd | NonPeoNeoAvgTotalCompAmt | NonPeoNeoAvgTotalCompAmt | USD | 898,197 | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-22 | 0001140361-26-016038 | ||
| ecd | PeoActuallyPaidCompAmt | PeoActuallyPaidCompAmt | USD | 958,175 | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-22 | 0001140361-26-016038 | ||
| ecd | PeoTotalCompAmt | PeoTotalCompAmt | USD | 1.67M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-22 | 0001140361-26-016038 | ||
| ecd | TotalShareholderRtnAmt | TotalShareholderRtnAmt | USD | 14.37 | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-22 | 0001140361-26-016038 | ||
| us-gaap | AccountsPayableCurrent | Accounts Payable, Current | USD | 1.64M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | AccretionAmortizationOfDiscountsAndPremiumsInvestments | Accretion (Amortization) of Discounts and Premiums, Investments | USD | 1.20M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | AccruedLiabilitiesCurrent | Accrued Liabilities, Current | USD | 8.91M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | AccruedProfessionalFeesCurrent | Accrued Professional Fees, Current | USD | 910,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment | Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | USD | 1.35M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | AccumulatedOtherComprehensiveIncomeLossNetOfTax | Accumulated Other Comprehensive Income (Loss), Net of Tax | USD | -156,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | AdditionalPaidInCapitalCommonStock | Additional Paid in Capital, Common Stock | USD | 574.21M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue | APIC, Share-based Payment Arrangement, Increase for Cost Recognition | USD | 1.60M | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | USD | 20,359 | 2020-01-01 | 2020-12-31 | 2022 | FY | 10-K | 2023-03-01 | 0000950170-23-005345 |
| us-gaap | AllocatedShareBasedCompensationExpense | Share-based Payment Arrangement, Expense | USD | 4.54M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 58.35M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | Assets | Assets | USD | 111.40M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | AssetsCurrent | Assets, Current | USD | 104.89M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | USD | 1,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | USD | 168,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | AvailableForSaleDebtSecuritiesAmortizedCostBasis | Debt Securities, Available-for-sale, Amortized Cost | USD | 108.64M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecurities | Debt Securities, Available-for-sale | USD | 108.48M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecuritiesCurrent | Debt Securities, Available-for-sale, Current | USD | 28.21M | 2019-12-31 | 2020 | FY | 10-K | 2021-03-03 | 0001564590-21-010578 | |
| us-gaap | Cash | Cash | USD | 254,000 | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-09 | 0000950170-23-061551 | |
| us-gaap | CashAndCashEquivalentsAtCarryingValue | Cash and Cash Equivalents, at Carrying Value | USD | 19.99M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | CashCashEquivalentsAndShortTermInvestments | Cash, Cash Equivalents, and Short-term Investments | USD | 108.52M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | USD | 19.99M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | USD | -17.99M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | CashEquivalentsAtCarryingValue | Cash Equivalents, at Carrying Value | USD | 19.99M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 | Class of Warrant or Right, Exercise Price of Warrants or Rights | USD/shares | 1.21 | 2026-09-02 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | ClassOfWarrantOrRightOutstanding | Class of Warrant or Right, Outstanding | shares | 41.95M | 2026-09-02 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | CommonStockCapitalSharesReservedForFutureIssuance | Common Stock, Capital Shares Reserved for Future Issuance | shares | 17.49M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 | |
| us-gaap | CommonStockParOrStatedValuePerShare | Common Stock, Par or Stated Value Per Share | USD/shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | CommonStockSharesAuthorized | Common Stock, Shares Authorized | shares | 1.00B | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | CommonStockSharesIssued | Common Stock, Shares, Issued | shares | 75.53M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | CommonStockSharesOutstanding | Common Stock, Shares, Outstanding | shares | 75.53M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | ComprehensiveIncomeNetOfTax | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | USD | -70.74M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | ConvertiblePreferredStockSharesIssuedUponConversion | Convertible Preferred Stock, Shares Issued upon Conversion | shares | 22.87M | 2019-12-31 | 2021 | FY | 10-K | 2022-03-01 | 0001564590-22-007860 | |
| us-gaap | CurrentFederalStateAndLocalTaxExpenseBenefit | Current Federal, State and Local, Tax Expense (Benefit) | USD | -2.17M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | CurrentForeignTaxExpenseBenefit | Current Foreign Tax Expense (Benefit) | USD | 22,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | CurrentStateAndLocalTaxExpenseBenefit | Current State and Local Tax Expense (Benefit) | USD | -2.19M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | DebtSecuritiesAvailableForSaleAllowanceForCreditLoss | Debt Securities, Available-for-sale, Allowance for Credit Loss | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | DebtSecuritiesAvailableForSaleUnrealizedGainLoss | Debt Securities, Available-for-sale, Unrealized Gain (Loss) | USD | 1.20M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | DeferredRentCredit | Deferred Rent Credit | USD | 88,000 | 2021-03-31 | 2021 | Q1 | 10-Q | 2021-05-14 | 0001564590-21-027813 | |
| us-gaap | DeferredTaxAssetsGross | Deferred Tax Assets, Gross | USD | 117.81M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 | |
| us-gaap | DeferredTaxAssetsLiabilitiesNet | Deferred Tax Assets, Net | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 | |
| us-gaap | DeferredTaxAssetsNet | Deferred Tax Assets, Net of Valuation Allowance | USD | 265,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwards | Deferred Tax Assets, Operating Loss Carryforwards | USD | 68.59M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 | |
| us-gaap | DeferredTaxAssetsTaxCreditCarryforwardsResearch | Deferred Tax Assets, Tax Credit Carryforwards, Research | USD | 11.79M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | USD | 3.68M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals | USD | 1.21M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 | |
| us-gaap | DeferredTaxAssetsValuationAllowance | Deferred Tax Assets, Valuation Allowance | USD | 117.54M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 | |
| us-gaap | DeferredTaxLiabilities | Deferred Tax Liabilities, Net | USD | 265,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 | |
| us-gaap | DeferredTaxLiabilitiesPropertyPlantAndEquipment | Deferred Tax Liabilities, Property, Plant and Equipment | USD | 27,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 | |
| us-gaap | Depreciation | Depreciation | USD | 81,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | DividendsCommonStock | Dividends, Common Stock | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | DividendsPreferredStock | Dividends, Preferred Stock | USD | 0 | 2019-01-01 | 2019-12-31 | 2021 | FY | 10-K | 2022-03-01 | 0001564590-22-007860 |
| us-gaap | EarningsPerShareBasic | Earnings Per Share, Basic | USD/shares | -1.22 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | EarningsPerShareBasicAndDiluted | Earnings Per Share, Basic and Diluted | USD/shares | -0.79 | 2022-01-01 | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-09 | 0000950170-22-015767 |
| us-gaap | EarningsPerShareDiluted | Earnings Per Share, Diluted | USD/shares | -1.22 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | EffectiveIncomeTaxRateContinuingOperations | Effective Income Tax Rate Reconciliation, Percent | pure | 0.03 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | pure | 0 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | pure | -0.22 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential | Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent | pure | -0.03 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | EffectiveIncomeTaxRateReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent | pure | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-02-29 | 0000950170-24-023062 |
| us-gaap | EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | pure | 0.02 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxContingencies | Effective Income Tax Rate Reconciliation, Tax Contingency, Percent | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCredits | Effective Income Tax Rate Reconciliation, Tax Credit, Percent | pure | -0.03 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | USD | 4,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions | Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount | USD | 305,000 | 2018-12-31 | 2020 | Q3 | 10-Q | 2020-11-13 | 0001564590-20-053908 | |
| us-gaap | EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | USD | 11.27M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | FairValueAdjustmentOfWarrants | Fair Value Adjustment of Warrants | USD | 12.78M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings | USD | 143,000 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-03 | 0001564590-21-010578 |
| us-gaap | FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | USD | 51,000 | 2019-12-31 | 2020 | FY | 10-K | 2021-03-03 | 0001564590-21-010578 | |
| us-gaap | GainLossOnSaleOfPropertyPlantEquipment | Gain (Loss) on Disposition of Property Plant Equipment | USD | -24,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | GainLossOnTerminationOfLease | Gain (Loss) on Termination of Lease | USD | 24,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | GeneralAndAdministrativeExpense | General and Administrative Expense | USD | 11.89M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic | Income (Loss) from Continuing Operations before Income Taxes, Domestic | USD | -79.94M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | USD | -70.50M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign | Income (Loss) from Continuing Operations before Income Taxes, Foreign | USD | 23,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | IncomeTaxesPaidNet | Income Taxes Paid, Net | USD | 23,000 | 2021-01-01 | 2021-12-31 | 2023 | FY | 10-K | 2024-02-29 | 0000950170-24-023062 |
| us-gaap | IncomeTaxExpenseBenefit | Income Tax Expense (Benefit) | USD | -4,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | USD | 17.25M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | IncomeTaxReconciliationForeignIncomeTaxRateDifferential | Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount | USD | 6,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | USD | -16.78M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | IncomeTaxReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount | USD | -1.84M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | IncomeTaxReconciliationTaxContingencies | Effective Income Tax Rate Reconciliation, Tax Contingency, Amount | USD | 745,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | IncomeTaxReconciliationTaxCredits | Effective Income Tax Rate Reconciliation, Tax Credit, Amount | USD | 2.54M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | IncreaseDecreaseInAccountsPayable | Increase (Decrease) in Accounts Payable | USD | -1.52M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | IncreaseDecreaseInAccruedLiabilities | Increase (Decrease) in Accrued Liabilities | USD | 1.06M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | IncreaseDecreaseInOperatingLeaseLiability | IncreaseDecreaseInOperatingLeaseLiability | USD | 241,000 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-03 | 0000950170-25-030414 |
| us-gaap | IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets | Increase (Decrease) in Prepaid Expense and Other Assets | USD | 24,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | InterestIncomeExpenseNet | Interest Income (Expense), Net | USD | 2.60M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | LeaseCost | Lease, Cost | USD | 387,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDue | Lessee, Operating Lease, Liability, to be Paid | USD | 1.01M | 2021-03-31 | 2021 | Q1 | 10-Q | 2021-05-14 | 0001564590-21-027813 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths | Lessee, Operating Lease, Liability, to be Paid, Year One | USD | 413,000 | 2021-03-31 | 2021 | Q1 | 10-Q | 2021-05-14 | 0001564590-21-027813 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearTwo | Lessee, Operating Lease, Liability, to be Paid, Year Two | USD | 71,000 | 2021-03-31 | 2021 | Q1 | 10-Q | 2021-05-14 | 0001564590-21-027813 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear | Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year | USD | 525,000 | 2021-03-31 | 2021 | Q1 | 10-Q | 2021-05-14 | 0001564590-21-027813 | |
| us-gaap | LesseeOperatingLeaseLiabilityUndiscountedExcessAmount | Lessee, Operating Lease, Liability, Undiscounted Excess Amount | USD | 2,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | Liabilities | Liabilities | USD | 54.30M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | LiabilitiesAndStockholdersEquity | Liabilities and Equity | USD | 111.40M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | LiabilitiesCurrent | Liabilities, Current | USD | 10.69M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | LiabilitiesFairValueDisclosure | Financial and Nonfinancial Liabilities, Fair Value Disclosure | USD | 43.61M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | MarketableSecurities | Marketable Securities | USD | 88.52M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | MarketableSecuritiesCurrent | Marketable Securities, Current | USD | 82.57M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | MarketableSecuritiesNoncurrent | Marketable Securities, Noncurrent | USD | 5.96M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | NetCashProvidedByUsedInFinancingActivities | Net Cash Provided by (Used in) Financing Activities | USD | 47.05M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | NetCashProvidedByUsedInInvestingActivities | Net Cash Provided by (Used in) Investing Activities | USD | -12.60M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | NetCashProvidedByUsedInOperatingActivities | Net Cash Provided by (Used in) Operating Activities | USD | -52.44M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | NetIncomeLoss | Net Income (Loss) Attributable to Parent | USD | -70.50M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | NumberOfOperatingSegments | Number of Operating Segments | Segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | NumberOfReportableSegments | Number of Reportable Segments | Segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | OperatingExpenses | Operating Expenses | USD | 57.96M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | OperatingIncomeLoss | Operating Income (Loss) | USD | -57.96M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | OperatingLeaseCost | Operating Lease, Cost | USD | 269,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | OperatingLeaseExpense | Operating Lease, Expense | USD | 269,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | OperatingLeaseLiability | Operating Lease, Liability | USD | 138,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | OperatingLeaseLiabilityCurrent | Operating Lease, Liability, Current | USD | 138,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | OperatingLeaseLiabilityNoncurrent | Operating Lease, Liability, Noncurrent | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | OperatingLeasePayments | Operating Lease, Payments | USD | 717,000 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-01 | 0001564590-22-007860 |
| us-gaap | OperatingLeaseRightOfUseAsset | Operating Lease, Right-of-Use Asset | USD | 133,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDue | Operating Leases, Future Minimum Payments Due | USD | 735,000 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-03 | 0001564590-21-010578 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueCurrent | Operating Leases, Future Minimum Payments Due, Next Twelve Months | USD | 479,000 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-03 | 0001564590-21-010578 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInThreeYears | Operating Leases, Future Minimum Payments, Due in Three Years | USD | 4,000 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-03 | 0001564590-21-010578 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInTwoYears | Operating Leases, Future Minimum Payments, Due in Two Years | USD | 252,000 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-03 | 0001564590-21-010578 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear | Operating Leases, Future Minimum Payments, Remainder of Fiscal Year | USD | 120,000 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-13 | 0001564590-20-053908 | |
| us-gaap | OperatingLeasesRentExpenseNet | Operating Leases, Rent Expense, Net | USD | 1.18M | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-12 | 0001564590-21-056458 |
| us-gaap | OperatingLeaseWeightedAverageDiscountRatePercent | Operating Lease, Weighted Average Discount Rate, Percent | pure | 0.137 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | OperatingLossCarryforwards | Operating Loss Carryforwards | USD | 97.67M | 2020-12-31 | 2020 | FY | 10-K | 2021-03-03 | 0001564590-21-010578 | |
| us-gaap | OtherAccruedLiabilitiesCurrent | Other Accrued Liabilities, Current | USD | 152,000 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-01 | 0000950170-23-005345 | |
| us-gaap | OtherAssetsNoncurrent | Other Assets, Noncurrent | USD | 291,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax | USD | -244,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax | USD | 4,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | OtherComprehensiveIncomeLossNetOfTax | Other Comprehensive Income (Loss), Net of Tax | USD | -240,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax | USD | -76,000 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | OtherLiabilitiesNoncurrent | Other Liabilities, Noncurrent | USD | 51,000 | 2019-12-31 | 2020 | FY | 10-K | 2021-03-03 | 0001564590-21-010578 | |
| us-gaap | OtherNoncashIncomeExpense | Other Noncash Income (Expense) | USD | -4,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | OtherNonoperatingIncomeExpense | Other Nonoperating Income (Expense) | USD | -12.54M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | PaymentsOfStockIssuanceCosts | Payments of Stock Issuance Costs | USD | 3.86M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | PaymentsToAcquireMarketableSecurities | Payments to Acquire Marketable Securities | USD | 78.57M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | PaymentsToAcquireProductiveAssets | Payments to Acquire Productive Assets | USD | 6,000 | 2023-01-01 | 2023-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | PaymentsToAcquirePropertyPlantAndEquipment | Payments to Acquire Property, Plant, and Equipment | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | PreferredStockParOrStatedValuePerShare | Preferred Stock, Par or Stated Value Per Share | USD/shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | PreferredStockSharesAuthorized | Preferred Stock, Shares Authorized | shares | 5.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | PreferredStockSharesIssued | Preferred Stock, Shares Issued | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | PreferredStockSharesOutstanding | Preferred Stock, Shares Outstanding | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | PrepaidExpenseAndOtherAssetsCurrent | Prepaid Expense and Other Assets, Current | USD | 2.33M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | ProceedsFromIssuanceOfCommonStock | Proceeds from Issuance of Common Stock | USD | 35.12M | 2023-01-01 | 2023-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | ProceedsFromIssuanceOfConvertiblePreferredStock | Proceeds from Issuance of Convertible Preferred Stock | USD | 69.79M | 2020-01-01 | 2020-12-31 | 2022 | FY | 10-K | 2023-03-01 | 0000950170-23-005345 |
| us-gaap | ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised | USD | 143,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | ProceedsFromSaleAndMaturityOfMarketableSecurities | Proceeds from Sale and Maturity of Marketable Securities | USD | 65.97M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | ProceedsFromSaleOfMachineryAndEquipment | Proceeds from Sale of Machinery and Equipment | USD | 29,000 | 2024-01-01 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-07 | 0000950170-24-122817 |
| us-gaap | ProceedsFromSaleOfPropertyPlantAndEquipment | Proceeds from Sale of Property, Plant, and Equipment | USD | 1,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | ProceedsFromStockOptionsExercised | Proceeds from Stock Options Exercised | USD | 0 | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-12 | 0001193125-26-218227 |
| us-gaap | ProfitLoss | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | USD | -70.50M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | PropertyPlantAndEquipmentGross | Property, Plant and Equipment, Gross | USD | 1.48M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | PropertyPlantAndEquipmentNet | Property, Plant and Equipment, Net | USD | 131,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | PurchaseCommitmentRemainingMinimumAmountCommitted | Purchase Commitment, Remaining Minimum Amount Committed | USD | 0 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-01 | 0001564590-22-007860 | |
| us-gaap | ReclassificationsOfTemporaryToPermanentEquity | Reclassifications of Temporary to Permanent Equity | USD | -238.72M | 2020-01-01 | 2020-12-31 | 2022 | FY | 10-K | 2023-03-01 | 0000950170-23-005345 |
| us-gaap | ResearchAndDevelopmentExpense | Research and Development Expense | USD | 46.07M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | RestrictedCash | Restricted Cash | USD | 0 | 2025-06-30 | 2025 | Q2 | 10-Q | 2025-08-07 | 0000950170-25-104588 | |
| us-gaap | RestrictedCashAndCashEquivalentsAtCarryingValue | Restricted Cash and Cash Equivalents, Current | USD | 177.46M | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-12 | 0001564590-21-056458 | |
| us-gaap | RestrictedCashCurrent | Restricted Cash, Current | USD | 822,000 | 2023-12-31 | 2024 | FY | 10-K | 2025-03-03 | 0000950170-25-030414 | |
| us-gaap | RetainedEarningsAccumulatedDeficit | Retained Earnings (Accumulated Deficit) | USD | -516.95M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | USD | 0 | 2025-01-01 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-12 | 0001193125-25-276003 |
| us-gaap | ShareBasedCompensation | Share-based Payment Arrangement, Noncash Expense | USD | 4.54M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | shares | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value | USD/shares | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | shares | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | USD/shares | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number | shares | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value | USD/shares | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period | shares | 907,665 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value | USD/shares | 1.8 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | pure | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | pure | 0.773 | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-12 | 0001193125-26-218227 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum | pure | 0.778 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum | pure | 0.769 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | pure | 0.038 | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-12 | 0001193125-26-218227 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum | pure | 0.051 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum | pure | 0.038 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant | Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | shares | 4.34M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 | |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | USD | 1.04M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | shares | 7.99M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | USD/shares | 2.9 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | shares | 117,680 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares | 4.53M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | USD/shares | 2.58 | 2018-01-01 | 2018-12-31 | 2020 | Q3 | 10-Q | 2020-11-13 | 0001564590-20-053908 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | USD | 2.85M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares | 16.38M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | USD/shares | 2.17 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value | USD | 2.85M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | shares | 16.38M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | USD/shares | 2.17 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | USD | 154.07M | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-03 | 0001564590-21-010578 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | shares | 2.59M | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-03 | 0001564590-21-010578 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | USD/shares | 1.37 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price | USD/shares | 1.98 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | USD/shares | 1.48 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | ShortTermLeaseCost | Short-term Lease, Cost | USD | 100,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | StockholdersEquity | Stockholders' Equity Attributable to Parent | USD | 57.11M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | StockholdersEquityNoteStockSplitConversionRatio1 | Stockholders' Equity Note, Stock Split, Conversion Ratio | pure | 5.265 | 2020-09-24 | 2022 | FY | 10-K | 2023-03-01 | 0000950170-23-005345 | |
| us-gaap | StockIssuedDuringPeriodSharesStockOptionsExercised | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares | 19,310 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | StockIssuedDuringPeriodValueConversionOfConvertibleSecurities | Stock Issued During Period, Value, Conversion of Convertible Securities | USD | 238.72M | 2020-01-01 | 2020-12-31 | 2022 | FY | 10-K | 2023-03-01 | 0000950170-23-005345 |
| us-gaap | StockIssuedDuringPeriodValueNewIssues | Stock Issued During Period, Value, New Issues | USD | 18.42M | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | StockIssuedDuringPeriodValueStockOptionsExercised | Stock Issued During Period, Value, Stock Options Exercised | USD | 10,000 | 2025-01-01 | 2025-03-31 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | TemporaryEquityCarryingAmountAttributableToParent | Temporary Equity, Carrying Amount, Attributable to Parent | USD | 168.93M | 2019-12-31 | 2021 | FY | 10-K | 2022-03-01 | 0001564590-22-007860 | |
| us-gaap | TemporaryEquityLiquidationPreference | Temporary Equity, Liquidation Preference | USD | 169.38M | 2019-12-31 | 2021 | FY | 10-K | 2022-03-01 | 0001564590-22-007860 | |
| us-gaap | TemporaryEquityParOrStatedValuePerShare | Temporary Equity, Par or Stated Value Per Share | USD/shares | 0 | 2019-12-31 | 2021 | FY | 10-K | 2022-03-01 | 0001564590-22-007860 | |
| us-gaap | TemporaryEquitySharesAuthorized | Temporary Equity, Shares Authorized | shares | 22.88M | 2019-12-31 | 2021 | FY | 10-K | 2022-03-01 | 0001564590-22-007860 | |
| us-gaap | TemporaryEquitySharesIssued | Temporary Equity, Shares Issued | shares | 22.87M | 2019-12-31 | 2021 | FY | 10-K | 2022-03-01 | 0001564590-22-007860 | |
| us-gaap | TemporaryEquitySharesOutstanding | Temporary Equity, Shares Outstanding | shares | 22.87M | 2019-12-31 | 2021 | FY | 10-K | 2022-03-01 | 0001564590-22-007860 | |
| us-gaap | UnrecognizedTaxBenefits | Unrecognized Tax Benefits | USD | 4.03M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 | |
| us-gaap | UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued | Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 | |
| us-gaap | UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions | USD | 773,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-06 | 0001193125-26-095014 |
| us-gaap | UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions | Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions | USD | 43,000 | 2021-01-01 | 2021-12-31 | 2022 | FY | 10-K | 2023-03-01 | 0000950170-23-005345 |
| us-gaap | VariableLeaseCost | Variable Lease, Cost | USD | 18,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | WarrantsAndRightsOutstanding | Warrants and Rights Outstanding | USD | 43.61M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 | |
| us-gaap | WeightedAverageNumberOfDilutedSharesOutstanding | Weighted Average Number of Shares Outstanding, Diluted | shares | 57.70M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | WeightedAverageNumberOfShareOutstandingBasicAndDiluted | Weighted Average Number of Shares Outstanding, Basic and Diluted | shares | 45.52M | 2022-01-01 | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-09 | 0000950170-22-015767 |
| us-gaap | WeightedAverageNumberOfSharesOutstandingBasic | Weighted Average Number of Shares Outstanding, Basic | shares | 57.70M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |
| us-gaap | WorkersCompensationLiabilityCurrent | Workers' Compensation Liability, Current | USD | 4.13M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-10 | 0001193125-26-454471 |